Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The Board determined the CFO would no longer serve, with no disclosed reason for the departure.
Tango Therapeutics CFO Daniella Beckman departs; Matthew Gall appointed new CFO
Filed April 15, 2026 · Period ending April 10, 2026 · ~1 min read
Key Changes
-
high
CFO Daniella Beckman ceased serving effective April 15, 2026, after the Board determined she would no longer hold the role. No reason for the departure was disclosed.
Item 5.02 verify on EDGAR → -
high
Matthew Gall, 49, appointed new CFO effective April 15, 2026. Previously served as CFO of Kalaris Therapeutics and iTeos Therapeutics, bringing biotech finance experience.
Item 5.02 verify on EDGAR → -
medium
Gall's compensation includes $540,000 base salary, 40% target bonus, options for 240,000 shares vesting over four years, and 40,000 restricted stock units vesting over three years.
Employment Agreement verify on EDGAR → -
medium
Jessica Newcomb, 40, Senior VP of Finance and CPA, appointed principal accounting officer effective April 15, 2026, splitting financial oversight responsibilities.
Item 5.02 verify on EDGAR →
Summary
Tango Therapeutics executed a sudden CFO transition, with Daniella Beckman departing and Matthew Gall stepping in on the same day, April 15, 2026. The Board made the determination to remove Beckman on April 10 but provided no explanation for the change, which raises questions about whether this was voluntary or performance-related.
Gall brings relevant biotech CFO experience from iTeos and Kalaris Therapeutics, and his compensation package appears market-standard for a small-cap biotech CFO. For retail investors, CFO changes can signal internal issues or simply reflect strategic shifts. The lack of explanation and quick turnaround (five days from Board decision to effective date) is notable.
The company split the principal accounting officer role to Jessica Newcomb, an internal promotion, which suggests some continuity in financial operations. Watch for the next earnings call or investor presentation where management discusses the transition. Also monitor whether Beckman's departure triggers any severance disclosures in upcoming proxy filings, which could provide more context about whether this was a negotiated exit or termination.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Tango Therapeutics disclosed leadership changes via press release on April 15, 2026.
Added in current filing · verify on EDGAR →
On April 15, 2026, the Company issued a press release announcing the leadership changes described above.
The company announced leadership changes through a press release. The 8-K references changes 'described above' but the body provided does not include Item 5.02 or other sections that would detail the specific nature of these changes (e.g., executive appointments, departures, role changes). The disclosure is furnished under Item 7.01 (Regulation FD) rather than filed, meaning it is not subject to Section 18 liability.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Employment Agreement, dated as of April 15, 2026 by and between the Company and Matthew Gall.
Tango Therapeutics has entered into an employment agreement with Matthew Gall effective April 15, 2026. The 8-K does not specify Mr. Gall's role or title, but the execution of a formal employment agreement and accompanying press release suggests this is a material hire. The specific terms, compensation, and responsibilities are contained in the attached exhibit.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
CFO Daniella Beckman departed; Matthew Gall appointed new CFO with $540K salary and equity grants; Jessica Newcomb named principal accounting officer.
Added in current filing · verify on EDGAR →
On April 10, 2026, the Board appointed Jessica Newcomb, 40, to serve as the Company’s principal accounting officer effective as of April 15, 2026.
Jessica Newcomb, age 40, was appointed principal accounting officer effective April 15, 2026. She currently serves as Senior Vice President, Finance at the Company, having joined in August 2022. She is a CPA and previously held controller roles at Acceleron Pharma.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify